市場調查報告書
商品編碼
995939

尿路感染的全球市場分析:未來預測(至2027年)

Urinary Tract Infection Market Research Report-Forecast till 2027

出版日期: | 出版商: Market Research Future | 英文 164 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

在分析期間(2020-2027年),全球尿路感染(UTI)市場預計在2019年將達到94億9,088萬美元,複合年增長率為3.62%。根據世界衛生組織(WHO)的數據,每年有100萬婦女因泌尿道感染而住院,這影響了全球約一半的女性人口。特別地,由於糖尿病患者經常發展該疾病,因此UTI患者的數量傾向於隨著糖尿病患者人數的增加而增加。按地區劃分,美洲佔世界的最大份額,為33.6%,其次是歐洲國家。另一方面,在亞太國家中,以中國,印度和韓國等人口稠密的國家為中心,預計未來市場將有顯著增長。

本報告分析了全球尿路感染(UTI)市場,並分析了該行業的基本結構和向心力,技術/法規環境,主要的市場促進/抑制因素,威脅類型/解決方案等。正在按最終用戶和地區,主要公司的概況,業務績效,策略等調查市場趨勢前景。

目錄

第1章執行摘要

第2章市場概述

第3章分析方法

第4章市場動態

  • 概述
  • 市場推廣因素
    • 糖尿病和腎結石的患病率增加
    • 推出組合藥物
  • 市場約束因素
    • 複雜的法規要求
  • 市場機會
    • 專注於促進新興市場和研發(R&D)

第5章市場因素分析

  • 價值鏈分析
    • 研發/設計
    • 製造業
    • 分銷/銷售
    • 售後服務
  • 波特的五種力量分析
  • 新的冠狀病毒感染(COVID-19)在尿路感染市場中的影響分析
    • 概述
    • 對供應鏈的影響
    • 對生產的影響

第6章全球尿道感染疾病市場:按藥物類別

  • 概述
  • 奎諾酮
  • GARMA-內□胺,頭孢菌素
  • 氨基糖甘
  • 青黴素
  • Azole

第7章全球尿道感染疾病市場:按用途

  • 概述
  • 尿道炎
  • 膀胱炎
  • 腎盂腎炎

第8章全球尿道感染市場:按病原菌

  • 概述
  • 大腸桿菌
  • 葡萄球菌
  • 克雷伯菌肺炎
  • 變形菌泥模
  • 糞腸球菌

第9章全球尿道感染疾病市場:按最終用戶分類

  • 概述
  • 醫院
  • 診所
  • 自我管理

第10章全球尿道感染疾病市場:按地區

  • 概述
  • 美洲
    • 北美
    • 拉丁美洲
  • 歐洲
    • 西歐
    • 東歐
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 韓國
    • 其他亞太國家
  • 中東/非洲
    • 中東
    • 非洲

第11章競爭情況

  • 概述
  • 公司之間的相互比較
  • 公司排名分析(2019)
  • 最近的主要趨勢和增長策略
    • 產品批准/發佈
    • 收購
  • 財務矩陣

第12章公司簡介

  • PFIZER INC.
  • NOVO NORDISK A/S
  • NOVARTIS AG
  • MERCK & CO., INC.
  • ELI LILY AND COMPANY
  • ALLERGAN
  • CIPLA INC.
  • TEVA PHARMACEUTICALS
  • GLAXOSMITHKLINE PLC
  • BAYER AG

第13章 附錄

目錄

Market Overview

Global Urinary Tract Infections Market is anticipated to exhibit a CAGR of 3.62% during the review period of 2020 to 2027. The infection in urinary system parts such as kidneys, ureters, bladder, and urethra are referred to as urinary tract infection. The major causes of UTI infection are unsafe sex, lack of hygiene, and diabetes.

Global Urinary Tract Infections Market is expected to register the highest market growth owing to the largest market value of USD 9,490.88 Million in 2019. As per the World Health Organization, 1 million hospitalizations of women occur each year due to UTIs, which affect almost half the female population around the world. Urological health issues are more common in diabetic patients. An increasing prevalence of diabetic population is expected to boost the global UTI patients worldwide. However, complex regulatory requirements are anticipated to restrain the growth of the global urinary tract infection market during the review period.

Market Segmentation

Global Urinary Tract Infections Market has been segmented into Drug Class, Application, Pathogen, End User.

In terms of drug class, the market has been classified into quinolones, B-lactam & cephalosporins, aminoglycosides, penicillin, and azoles. The quinolones segment is further sub-divided into ciprofloxacin, enoxacin, norfloxacin, ofloxacin, pefloxacin, and fleroxacin. The cephalosporin is again classified into avycaz, cedax, cefdinir, and cefditoren. The B-lactam is further divided into amoxicillin-clavulanate, cefdinir, cefaclor, and cefpodoxime-proxetil.

The Global Urinary Tract Infections Market, based on application, has been divided into urethritis, cystitis, and pyelonephritis. In terms of the pathogen, the market has been categorized into Escherichia coli, Staphylococcus saprophyticus, Klebsiella pneumoniae, Proteus mirabilis, and Enterococcus faecalis. By end-user category, the global urinary tract infections market has been classified into hospitals, clinics, self-administered, and others.

Regional Analysis

Geographically, the global UTI market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas is likely to dominate the global market owing to the largest market share of 33.6% of the global market in 2019. The regional market growth is driven by the presence of key manufacturers, the increasing prevalence of urinary tract infections, and the increasing aging woman population in the region. The market in the Americas is categorized into North America and Latin America. Additionally, the global market growth is driven by the increasing technological advancements in diagnostics and therapeutic products coupled with the rising prevalence of urinary tract diseases and other kidney problems.

Europe is expected to register the second-largest market of the Global Urinary Tract Infection. The regional market is segmented into France, Germany, Italy, Spain, and the UK. The regional market growth is attributed to the increasing awareness of urinary tract diseases, increasing educational activity, and the availability of different diagnostic and therapeutic methods to manage the infection. Asia-Pacific is set to exhibit the fastest-growing market for UTI during the review period. The regional market growth is driven by the developing economies and highly populated countries such as China, India, and South Korea.

Major Players

The Prominent Players in the Global Urinary Tract Infections Market are Pfizer Inc., Novo Nordisk A/S, Novartis Ag, Merck & Co., Inc., Eli Lily and Company, Allergan, Cipla Inc., Teva Pharmaceuticals, GlaxoSmithKline plc, and Bayer AG.

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

  • 1.1 MARKET ATTRACTIVENESS ANALYSIS 18

2 MARKET INTRODUCTION

  • 2.1 DEFINITION 19
  • 2.2 SCOPE OF THE STUDY 19
  • 2.3 RESEARCH OBJECTIVE 19
  • 2.4 MARKET STRUCTURE 19
  • 2.5 ASSUMPTIONS & LIMITATIONS 20

3 RESEARCH METHODOLOGY

  • 3.1 DATA MINING 21
  • 3.2 SECONDARY RESEARCH 22
  • 3.3 PRIMARY RESEARCH 23
  • 3.4 BREAKDOWN OF PRIMARY RESPONDENTS 24
  • 3.5 FORECASTING TECHNIQUES 25
  • 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 26
    • 3.6.1 BOTTOM-UP APPROACH 27
    • 3.6.2 TOP-DOWN APPROACH 27
  • 3.7 DATA TRIANGULATION 28
  • 3.8 VALIDATION 28

4 MARKET DYNAMICS

  • 4.1 OVERVIEW 29
  • 4.2 DRIVERS 30
    • 4.2.1 INCREASING PREVALENCE OF DIABETES AND KIDNEY STONES 30
    • 4.2.2 LAUNCH OF COMBINATION DRUGS 30
  • 4.3 RESTRAINTS 31
    • 4.3.1 COMPLEX REGULATORY REQUIREMENTS 31
  • 4.4 OPPORTUNITIES 32
    • 4.4.1 FOCUS ON EMERGING ECONOMIES AND BOOSTING R&D 32

5 MARKET FACTOR ANALYSIS

  • 5.1 VALUE CHAIN ANALYSIS 33
    • 5.1.1 R&D AND DESIGNING 34
    • 5.1.2 MANUFACTURING 34
    • 5.1.3 DISTRIBUTION & SALES 34
    • 5.1.4 POST-SALES SERVICES 34
  • 5.2 PORTER'S FIVE FORCES MODEL 35
    • 5.2.1 BARGAINING POWER OF SUPPLIERS 36
    • 5.2.2 BARGAINING POWER OF BUYERS 36
    • 5.2.3 THREAT OF NEW ENTRANTS 36
    • 5.2.4 THREAT OF SUBSTITUTES 36
    • 5.2.5 RIVALRY 36
  • 5.3 IMPACT ANALYSIS OF COVID-19 ON URINARY TRACT INFECTION MARKET 37
    • 5.3.1 OVERVIEW 37
    • 5.3.2 IMPACT ON SUPPLY CHAIN 37
    • 5.3.3 IMPACT ON PRODUCTION 38

6 GLOBAL URINARY TRACT INFECTION MARKET BY DRUG CLASS

  • 6.1 OVERVIEW 40
  • 6.2 QUINOLONES 42
  • 6.3 -LACTAM & CEPHALOSPORINS 43
  • 6.4 AMINOGLYCOSIDES 44
  • 6.5 PENICILLIN 44
  • 6.6 AZOLES 45

7 GLOBAL URINARY TRACT INFECTION MARKET BY APPLICATION

  • 7.1 OVERVIEW 46
  • 7.2 URETHRITIS 47
  • 7.3 CYSTITIS 48
  • 7.4 PYELONEPHRITIS 48

8 GLOBAL URINARY TRACT INFECTION MARKET BY PATHOGEN

  • 8.1 OVERVIEW 49
  • 8.2 ESCHERICHIA COLI 50
  • 8.3 STAPHYLOCOCCUS SAPROPHYTICUS 51
  • 8.4 KLEBSIELLA PNEUMONIAE 51
  • 8.5 PROTEUS MIRABILIS 52
  • 8.6 ENTEROCOCCUS FAECALIS 52

9 GLOBAL URINARY TRACT INFECTION MARKET BY END USER

  • 9.1 OVERVIEW 53
  • 9.2 HOSPITALS 54
  • 9.3 CLINICS 54
  • 9.4 SELF-ADMINISTERED 55

10 GLOBAL URINARY TRACT INFECTION MARKET BY REGION

  • 10.1 OVERVIEW 56
  • 10.2 AMERICAS 58
    • 10.2.1 NORTH AMERICA 61
      • 10.2.1.1 US 64
      • 10.2.1.2 CANADA 67
    • 10.2.2 LATIN AMERICA 70
  • 10.3 EUROPE 73
    • 10.3.1 WESTERN EUROPE 76
      • 10.3.1.1 GERMANY 80
      • 10.3.1.2 FRANCE 83
      • 10.3.1.3 UK 86
      • 10.3.1.4 ITALY 89
      • 10.3.1.5 SPAIN 92
      • 10.3.1.6 REST OF WESTERN EUROPE 95
    • 10.3.2 EASTERN EUROPE 98
  • 10.4 ASIA-PACIFIC 101
    • 10.4.1 CHINA 105
    • 10.4.2 INDIA 108
    • 10.4.3 JAPAN 111
    • 10.4.4 AUSTRALIA 114
    • 10.4.5 SOUTH KOREA 117
    • 10.4.6 REST OF ASIA-PACIFIC 120
  • 10.5 MIDDLE EAST & AFRICA 123
    • 10.5.1 MIDDLE EAST 126
    • 10.5.2 AFRICA 129

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW 132
  • 11.2 COMPETITIVE BENCHMARKING 133
  • 11.3 GLOBAL URINARY TRACT INFECTION MARKET: COMPANY RANKING, 2019 134
  • 11.4 KEY DEVELOPMENTS & GROWTH STRATEGIES 134
    • 11.4.1 PRODUCT APPROVALS AND LAUNCHES 134
    • 11.4.2 ACQUISITIONS 134
  • 11.5 FINANCIAL MATRIX 135

12 COMPANY PROFILES

  • 12.1 PFIZER INC. 136
    • 12.1.1 COMPANY OVERVIEW 136
    • 12.1.2 FINANCIAL OVERVIEW 137
    • 12.1.3 PRODUCTS/SERVICES OFFERED 138
    • 12.1.4 KEY DEVELOPMENTS 138
    • 12.1.5 SWOT ANALYSIS 138
    • 12.1.6 KEY STRATEGIES 139
  • 12.2 NOVO NORDISK A/S 140
    • 12.2.1 COMPANY OVERVIEW 140
    • 12.2.2 FINANCIAL OVERVIEW 140
    • 12.2.3 PRODUCTS/SERVICES OFFERED 141
    • 12.2.4 KEY DEVELOPMENTS 141
    • 12.2.5 SWOT ANALYSIS 141
    • 12.2.6 KEY STRATEGIES 141
  • 12.3 NOVARTIS AG 142
    • 12.3.1 COMPANY OVERVIEW 142
    • 12.3.2 FINANCIAL OVERVIEW 142
    • 12.3.3 PRODUCTS/SERVICES OFFERED 143
    • 12.3.4 KEY DEVELOPMENTS 143
    • 12.3.5 SWOT ANALYSIS 143
    • 12.3.6 KEY STRATEGIES 144
  • 12.4 MERCK & CO., INC. 145
    • 12.4.1 COMPANY OVERVIEW 145
    • 12.4.2 FINANCIAL OVERVIEW 145
    • 12.4.3 PRODUCTS/SERVICES OFFERED 146
    • 12.4.4 KEY DEVELOPMENTS 146
    • 12.4.5 SWOT ANALYSIS 146
    • 12.4.6 KEY STRATEGIES 146
  • 12.5 ELI LILY AND COMPANY 147
    • 12.5.1 COMPANY OVERVIEW 147
    • 12.5.2 FINANCIAL OVERVIEW 147
    • 12.5.3 PRODUCTS/SERVICES OFFERED 148
    • 12.5.4 KEY DEVELOPMENTS 148
    • 12.5.5 SWOT ANALYSIS 148
    • 12.5.6 KEY STRATEGIES 148
  • 12.6 ALLERGAN 149
    • 12.6.1 COMPANY OVERVIEW 149
    • 12.6.2 FINANCIAL OVERVIEW 149
    • 12.6.3 PRODUCTS/SERVICES OFFERED 150
    • 12.6.4 KEY DEVELOPMENTS 150
    • 12.6.5 SWOT ANALYSIS 150
    • 12.6.6 KEY STRATEGIES 150
  • 12.7 CIPLA INC. 151
    • 12.7.1 COMPANY OVERVIEW 151
    • 12.7.2 FINANCIAL OVERVIEW 151
    • 12.7.3 PRODUCTS/SERVICES OFFERED 151
    • 12.7.4 KEY DEVELOPMENTS 151
    • 12.7.5 SWOT ANALYSIS 152
    • 12.7.6 KEY STRATEGIES 152
  • 12.8 TEVA PHARMACEUTICALS 153
    • 12.8.1 COMPANY OVERVIEW 153
    • 12.8.2 FINANCIAL OVERVIEW 153
    • 12.8.3 PRODUCTS/SERVICES OFFERED 154
    • 12.8.4 KEY DEVELOPMENTS 154
    • 12.8.5 SWOT ANALYSIS 154
    • 12.8.6 KEY STRATEGIES 155
  • 12.9 GLAXOSMITHKLINE PLC 156
    • 12.9.1 COMPANY OVERVIEW 156
    • 12.9.2 FINANCIAL OVERVIEW 156
    • 12.9.3 PRODUCTS/SERVICES OFFERED 157
    • 12.9.4 KEY DEVELOPMENTS 157
    • 12.9.5 SWOT ANALYSIS 157
    • 12.9.6 KEY STRATEGIES 157
  • 12.10 BAYER AG 158
    • 12.10.1 COMPANY OVERVIEW 158
    • 12.10.2 COMPANY VALUE 158
    • 12.10.3 FINANCIAL OVERVIEW 159
    • 12.10.4 PRODUCTS/SERVICES OFFERED 159
    • 12.10.5 KEY DEVELOPMENTS 159
    • 12.10.6 SWOT ANALYSIS 160
    • 12.10.7 KEY STRATEGIES 160

13 APPENDIX

  • 13.1 REFERENCES 161
  • 13.2 RELATED REPORTS 161

LIST OF TABLES

  • TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS 20
  • TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 23
  • TABLE 3 GLOBAL URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 41
  • TABLE 4 GLOBAL URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY REGION, 2017-2027 (USD MILLION) 42
  • TABLE 5 GLOBAL URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 42
  • TABLE 6 GLOBAL URINARY TRACT INFECTION MARKET, FOR -LACTAM & CEPHALOSPORINS, BY REGION, 2017-2027 (USD MILLION) 43
  • TABLE 7 GLOBAL URINARY TRACT INFECTION MARKET, FOR -LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 43
  • TABLE 8 GLOBAL URINARY TRACT INFECTION MARKET, FOR AMINOGLYCOSIDES, BY REGION, 2017-2027 (USD MILLION) 44
  • TABLE 9 GLOBAL URINARY TRACT INFECTION MARKET, FOR PENICILLIN, BY REGION, 2017-2027 (USD MILLION) 44
  • TABLE 10 GLOBAL URINARY TRACT INFECTION MARKET, FOR AZOLES, BY REGION, 2017-2027 (USD MILLION) 45
  • TABLE 11 GLOBAL URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 47
  • TABLE 12 GLOBAL URINARY TRACT INFECTION MARKET, FOR URETHRITIS, BY REGION, 2017-2027 (USD MILLION) 47
  • TABLE 13 GLOBAL URINARY TRACT INFECTION MARKET, FOR CYSTITIS, BY REGION, 2017-2027 (USD MILLION) 48
  • TABLE 14 GLOBAL URINARY TRACT INFECTION MARKET, FOR PYELONEPHRITIS, BY REGION, 2017-2027 (USD MILLION) 48
  • TABLE 15 GLOBAL URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 50
  • TABLE 16 GLOBAL URINARY TRACT INFECTION MARKET, FOR ESCHERICHIA COLI, BY REGION, 2017-2027 (USD MILLION) 50
  • TABLE 17 GLOBAL URINARY TRACT INFECTION MARKET, FOR STAPHYLOCOCCUS SAPROPHYTICUS, BY REGION, 2017-2027 (USD MILLION) 51
  • TABLE 18 GLOBAL URINARY TRACT INFECTION MARKET, FOR KLEBSIELLA PNEUMONIAE, BY REGION, 2017-2027 (USD MILLION) 51
  • TABLE 19 GLOBAL URINARY TRACT INFECTION MARKET, FOR PROTEUS MIRABILIS, BY REGION, 2017-2027 (USD MILLION) 52
  • TABLE 20 GLOBAL URINARY TRACT INFECTION MARKET, FOR ENTEROCOCCUS FAECALIS, BY REGION, 2017-2027 (USD MILLION) 52
  • TABLE 21 GLOBAL URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 54
  • TABLE 22 GLOBAL URINARY TRACT INFECTION MARKET, FOR HOSPITALS, BY REGION, 2017-2027 (USD MILLION) 54
  • TABLE 23 GLOBAL URINARY TRACT INFECTION MARKET, FOR CLINICS, BY REGION, 2017-2027 (USD MILLION) 54
  • TABLE 24 GLOBAL URINARY TRACT INFECTION MARKET, FOR SELF-ADMINISTERED, BY REGION, 2017-2027 (USD MILLION) 55
  • TABLE 25 GLOBAL URINARY TRACT INFECTION MARKET, BY REGION, 2017-2027 (USD MILLION) 57
  • TABLE 26 AMERICAS: URINARY TRACT INFECTION MARKET, BY REGION, 2017-2027 (USD MILLION) 58
  • TABLE 27 AMERICAS: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 58
  • TABLE 28 AMERICAS: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 59
  • TABLE 29 AMERICAS: URINARY TRACT INFECTION MARKET, FOR -LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 59
  • TABLE 30 AMERICAS: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 60
  • TABLE 31 AMERICAS: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 60
  • TABLE 32 AMERICAS: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 60
  • TABLE 33 NORTH AMERICA: URINARY TRACT INFECTION MARKET, BY COUNTRY, 2017-2027 (USD MILLION) 61
  • TABLE 34 NORTH AMERICA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 61
  • TABLE 35 NORTH AMERICA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 62
  • TABLE 36 NORTH AMERICA: URINARY TRACT INFECTION MARKET, FOR -LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 62
  • TABLE 37 NORTH AMERICA: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 63
  • TABLE 38 NORTH AMERICA: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 63
  • TABLE 39 NORTH AMERICA: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 63
  • TABLE 40 NORTH AMERICA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 64
  • TABLE 41 US: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 64
  • TABLE 42 US: URINARY TRACT INFECTION MARKET, FOR -LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 65
  • TABLE 43 US: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 65
  • TABLE 44 US: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 66
  • TABLE 45 US: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 66
  • TABLE 46 CANADA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 67
  • TABLE 47 CANADA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 67
  • TABLE 48 CANADA: URINARY TRACT INFECTION MARKET, FOR -LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 68
  • TABLE 49 CANADA: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 68
  • TABLE 50 CANADA: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 69
  • TABLE 51 CANADA: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 69
  • TABLE 52 LATIN AMERICA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 70
  • TABLE 53 LATIN AMERICA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 70
  • TABLE 54 LATIN AMERICA: URINARY TRACT INFECTION MARKET, FOR -LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 71
  • TABLE 55 LATIN AMERICA: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 72
  • TABLE 56 LATIN AMERICA: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 72
  • TABLE 57 LATIN AMERICA: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 72
  • TABLE 58 EUROPE: URINARY TRACT INFECTION MARKET, BY REGION, 2017-2027 (USD MILLION) 73
  • TABLE 59 EUROPE: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 73
  • TABLE 60 EUROPE: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 74
  • TABLE 61 EUROPE: URINARY TRACT INFECTION MARKET, FOR -LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 74
  • TABLE 62 EUROPE: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 75
  • TABLE 63 EUROPE: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 75
  • TABLE 64 EUROPE: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 75
  • TABLE 65 WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY COUNTRY, 2017-2027 (USD MILLION) 76
  • TABLE 66 WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 77
  • TABLE 67 WESTERN EUROPE: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 77
  • TABLE 68 WESTERN EUROPE: URINARY TRACT INFECTION MARKET, FOR -LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 78
  • TABLE 69 WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 78
  • TABLE 70 WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 79
  • TABLE 71 WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 79
  • TABLE 72 GERMANY: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 80
  • TABLE 73 GERMANY: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 80
  • TABLE 74 GERMANY: URINARY TRACT INFECTION MARKET, FOR -LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 81
  • TABLE 75 GERMANY: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 81
  • TABLE 76 GERMANY: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 82
  • TABLE 77 GERMANY: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 82
  • TABLE 78 FRANCE: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 83
  • TABLE 79 FRANCE: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 83
  • TABLE 80 FRANCE: URINARY TRACT INFECTION MARKET, FOR -LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 84
  • TABLE 81 FRANCE: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 84
  • TABLE 82 FRANCE: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 85
  • TABLE 83 FRANCE: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 85
  • TABLE 84 UK: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 86
  • TABLE 85 UK: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 86
  • TABLE 86 UK: URINARY TRACT INFECTION MARKET, FOR -LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 87
  • TABLE 87 UK: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 87
  • TABLE 88 UK: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 88
  • TABLE 89 UK: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 88
  • TABLE 90 ITALY: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 89
  • TABLE 91 ITALY: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 89
  • TABLE 92 ITALY: URINARY TRACT INFECTION MARKET, FOR -LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 90
  • TABLE 93 ITALY: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 90
  • TABLE 94 ITALY: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 91
  • TABLE 95 ITALY: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 91
  • TABLE 96 SPAIN: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 92
  • TABLE 97 SPAIN: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 92
  • TABLE 98 SPAIN: URINARY TRACT INFECTION MARKET, FOR -LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 93
  • TABLE 99 SPAIN: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 93
  • TABLE 100 SPAIN: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 94
  • TABLE 101 SPAIN: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 94
  • TABLE 102 REST OF WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 95
  • TABLE 103 REST OF WESTERN EUROPE: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 95
  • TABLE 104 REST OF WESTERN EUROPE: URINARY TRACT INFECTION MARKET, FOR -LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 96
  • TABLE 105 REST OF WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 96
  • TABLE 106 REST OF WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 97
  • TABLE 107 REST OF WESTERN EUROPE: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 97
  • TABLE 108 EASTERN EUROPE: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 98
  • TABLE 109 EASTERN EUROPE: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 98
  • TABLE 110 EASTERN EUROPE: URINARY TRACT INFECTION MARKET, FOR -LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 99
  • TABLE 111 EASTERN EUROPE: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 99
  • TABLE 112 EASTERN EUROPE: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 100
  • TABLE 113 EASTERN EUROPE: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 100
  • TABLE 114 ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, BY COUNTRY, 2017-2027 (USD MILLION) 101
  • TABLE 115 ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 102
  • TABLE 116 ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 102
  • TABLE 117 ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, FOR -LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 103
  • TABLE 118 ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 103
  • TABLE 119 ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 104
  • TABLE 120 ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 104
  • TABLE 121 CHINA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 105
  • TABLE 122 CHINA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 105
  • TABLE 123 CHINA: URINARY TRACT INFECTION MARKET, FOR -LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 106
  • TABLE 124 CHINA: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 106
  • TABLE 125 CHINA: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 107
  • TABLE 126 CHINA: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 107
  • TABLE 127 INDIA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 108
  • TABLE 128 INDIA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 108
  • TABLE 129 INDIA: URINARY TRACT INFECTION MARKET, FOR -LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 109
  • TABLE 130 INDIA: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 109
  • TABLE 131 INDIA: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 110
  • TABLE 132 INDIA: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 110
  • TABLE 133 JAPAN: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 111
  • TABLE 134 JAPAN: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 111
  • TABLE 135 JAPAN: URINARY TRACT INFECTION MARKET, FOR -LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 112
  • TABLE 136 JAPAN: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 112
  • TABLE 137 JAPAN: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 113
  • TABLE 138 JAPAN: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 113
  • TABLE 139 AUSTRALIA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 114
  • TABLE 140 AUSTRALIA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 114
  • TABLE 141 AUSTRALIA: URINARY TRACT INFECTION MARKET, FOR -LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 115
  • TABLE 142 AUSTRALIA: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 115
  • TABLE 143 AUSTRALIA: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 116
  • TABLE 144 AUSTRALIA: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 116
  • TABLE 145 SOUTH KOREA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 117
  • TABLE 146 SOUTH KOREA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 117
  • TABLE 147 SOUTH KOREA: URINARY TRACT INFECTION MARKET, FOR -LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 118
  • TABLE 148 SOUTH KOREA: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 118
  • TABLE 149 SOUTH KOREA: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 119
  • TABLE 150 SOUTH KOREA: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 119
  • TABLE 151 REST OF ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 120
  • TABLE 152 REST OF ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 120
  • TABLE 153 REST OF ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, FOR -LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 121
  • TABLE 154 REST OF ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 121
  • TABLE 155 REST OF ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 122
  • TABLE 156 REST OF ASIA-PACIFIC: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 122
  • TABLE 157 MIDDLE EAST & AFRICA: URINARY TRACT INFECTION MARKET, BY REGION, 2017-2027 (USD MILLION) 123
  • TABLE 158 MIDDLE EAST & AFRICA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 123
  • TABLE 159 MIDDLE EAST & AFRICA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 124
  • TABLE 160 MIDDLE EAST & AFRICA: URINARY TRACT INFECTION MARKET, FOR -LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 124
  • TABLE 161 MIDDLE EAST & AFRICA: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 125
  • TABLE 162 MIDDLE EAST & AFRICA: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 125
  • TABLE 163 MIDDLE EAST & AFRICA: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 125
  • TABLE 164 MIDDLE EAST: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 126
  • TABLE 165 MIDDLE EAST: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 126
  • TABLE 166 MIDDLE EAST: URINARY TRACT INFECTION MARKET, FOR -LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 127
  • TABLE 167 MIDDLE EAST: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 127
  • TABLE 168 MIDDLE EAST: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 128
  • TABLE 169 MIDDLE EAST: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 128
  • TABLE 170 AFRICA: URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2017-2027 (USD MILLION) 129
  • TABLE 171 AFRICA: URINARY TRACT INFECTION MARKET, FOR QUINOLONES, BY TYPE, 2017-2027 (USD MILLION) 129
  • TABLE 172 AFRICA: URINARY TRACT INFECTION MARKET, FOR -LACTAM & CEPHALOSPORINS, BY TYPE, 2017-2027 (USD MILLION) 130
  • TABLE 173 AFRICA: URINARY TRACT INFECTION MARKET, BY APPLICATION, 2017-2027 (USD MILLION) 130
  • TABLE 174 AFRICA: URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2017-2027 (USD MILLION) 131
  • TABLE 175 AFRICA: URINARY TRACT INFECTION MARKET, BY END USER, 2017-2027 (USD MILLION) 131
  • TABLE 176 MAJOR MANUFACTURERS RANKING, 2019 134
  • TABLE 177 PRODUCT APPROVALS AND LAUNCHES 134
  • TABLE 178 ACQUISITIONS 134
  • TABLE 179 PFIZER INC.: PRODUCTS/SERVICES OFFERED 138
  • TABLE 180 NOVO NORDISK A/S: PRODUCTS/SERVICES OFFERED 141
  • TABLE 181 NOVARTIS AG: PRODUCTS/SERVICES OFFERED 143
  • TABLE 182 MERCK & CO., INC.: PRODUCTS/SERVICES OFFERED 146
  • TABLE 183 ELI LILY AND COMPANY: PRODUCTS/SERVICES OFFERED 148
  • TABLE 184 ALLERGAN: PRODUCTS/SERVICES OFFERED 150
  • TABLE 185 CIPLA INC.: PRODUCTS/SERVICES OFFERED 151
  • TABLE 186 CIPLA INC.: KEY DEVELOPMENTS 151
  • TABLE 187 TEVA PHARMACEUTICALS: PRODUCTS/SERVICES OFFERED 154
  • TABLE 188 TEVA PHARMACEUTICALS: KEY DEVELOPMENTS 154
  • TABLE 189 GLAXOSMITHKLINE PLC: PRODUCTS/SERVICES OFFERED 157
  • TABLE 190 BAYER AG: COMPANY VALUE 158
  • TABLE 191 BAYER AG.: PRODUCTS/SERVICES OFFERED 159

LIST OF FIGURES

  • FIGURE 1 MARKET SYNOPSIS 17
  • FIGURE 2 MARKET ATTRACTIVENESS ANALYSIS, BY REGION, 2019 18
  • FIGURE 3 GLOBAL URINARY TRACT INFECTION MARKET: STRUCTURE 19
  • FIGURE 4 BOTTOM-UP AND TOP-DOWN APPROACHES 26
  • FIGURE 5 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL URINARY TRACT INFECTION (UTI) MARKET 29
  • FIGURE 6 DRIVER IMPACT ANALYSIS 31
  • FIGURE 7 RESTRAINT IMPACT ANALYSIS 32
  • FIGURE 8 VALUE CHAIN: GLOBAL URINARY TRACT INFECTION MARKET 33
  • FIGURE 9 PORTER'S FIVE FORCES ANALYSIS: GLOBAL URINARY TRACT INFECTION MARKET 35
  • FIGURE 10 GLOBAL URINARY TRACT INFECTION MARKET, BY DRUG CLASS, 2019 AND 2027 (USD MILLION) 41
  • FIGURE 11 GLOBAL URINARY TRACT INFECTION MARKET, BY APPLICATION, 2019 AND 2027 (USD MILLION) 46
  • FIGURE 12 GLOBAL URINARY TRACT INFECTION MARKET, BY PATHOGEN, 2019 AND 2027 (USD MILLION) 49
  • FIGURE 13 GLOBAL URINARY TRACT INFECTION MARKET, BY END USER, 2019 AND 2027 (USD MILLION) 53
  • FIGURE 14 GLOBAL URINARY TRACT INFECTION MARKET, BY REGION, 2019 AND 2027 (USD MILLION) 57
  • FIGURE 15 AMERICAS: URINARY TRACT INFECTION MARKET SHARE, BY REGION, 2019 (%) 58
  • FIGURE 16 NORTH AMERICA: URINARY TRACT INFECTION MARKET SHARE, BY COUNTRY, 2019 (%) 61
  • FIGURE 17 EUROPE: URINARY TRACT INFECTION MARKET SHARE, BY REGION, 2019 (%) 73
  • FIGURE 18 WESTERN EUROPE: URINARY TRACT INFECTION MARKET SHARE, BY COUNTRY, 2019 (%) 76
  • FIGURE 19 ASIA-PACIFIC: URINARY TRACT INFECTION MARKET SHARE, BY COUNTRY, 2019 (%) 101
  • FIGURE 20 MIDDLE EAST & AFRICA: URINARY TRACT INFECTION MARKET SHARE, BY REGION, 2019 (%) 123
  • FIGURE 21 BENCHMARKING OF MAJOR COMPETITORS 133
  • FIGURE 22 SALES & OPERATING INCOME MARGIN, 2019 135
  • FIGURE 23 RESEARCH & DEVELOPMENT EXPENDITURE, 2019 135
  • FIGURE 24 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT 137
  • FIGURE 25 PFIZER INC.: SWOT ANALYSIS 138
  • FIGURE 26 NOVO NORDISK A/S: FINANCIAL OVERVIEW SNAPSHOT 140
  • FIGURE 27 NOVO NORDISK A/S: SWOT ANALYSIS 141
  • FIGURE 28 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT 142
  • FIGURE 29 NOVARTIS AG: SWOT ANALYSIS 143
  • FIGURE 30 MERCK & CO., INC.: FINANCIAL OVERVIEW SNAPSHOT 145
  • FIGURE 31 MERCK & CO., INC.: SWOT ANALYSIS 146
  • FIGURE 32 ELI LILY AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT 147
  • FIGURE 33 ELI LILY AND COMPANY: SWOT ANALYSIS 148
  • FIGURE 34 ALLERGAN: FINANCIAL OVERVIEW SNAPSHOT 149
  • FIGURE 35 ALLERGAN: SWOT ANALYSIS 150
  • FIGURE 36 CIPLA INC.: SWOT ANALYSIS 152
  • FIGURE 37 TEVA PHARMACEUTICALS: FINANCIAL OVERVIEW SNAPSHOT 153
  • FIGURE 38 TEVA PHARMACEUTICALS: SWOT ANALYSIS 154
  • FIGURE 39 GLAXOSMITHKLINE PLC: FINANCIAL OVERVIEW SNAPSHOT 156
  • FIGURE 40 GLAXOSMITHKLINE PLC: SWOT ANALYSIS 157
  • FIGURE 41 BAYER AG.: FINANCIAL OVERVIEW SNAPSHOT 159
  • FIGURE 42 BAYER AG.: SWOT ANALYSIS 160